Symbiotec Pharmalab Q1 FY27: Revenue ₹218.2 Cr, EBITDA margin 21%
Q1 FY27 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹218Cr
- −11% QoQ
- Net profit
- ₹14Cr
- −50% QoQ
- Margin
- 21%
- −4 pp QoQ
Guidance rank: #27 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Symbiotec Pharmalab Ltd Q1 FY27 key numbers
- Revenue
- API EBITDA increased 9% YoY to ₹65.8 crores, with ~30% EBITDA margin maintained.
As stated in Symbiotec Pharmalab Ltd's Q1 FY27 investor presentation · published 25 Sept 2026. Reported figures, not investment advice.
Based on Symbiotec Pharmalab Ltd's Q1 FY27 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Q1 FY27 EBITDA: Rs. 45.2 Cr, down from Rs. 58.0 Cr in Q1 FY26 (22% decline YoY).
From Symbiotec Pharmalab Ltd's Q1 FY27 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9).
- API business revenue for Q1 FY27: ₹215.3 crores, up 6% YoY (Page 7).
- Q1 FY27 gross margins at 65%, up 300 basis points YoY (Page 9).
- API EBITDA increased 9% YoY to ₹65.8 crores, with ~30% EBITDA margin maintained (Page 7).
- Management commentary projects API revenue growth expected to further pick up in subsequent quarters (Page 6).
2 more points from Symbiotec Pharmalab Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Symbiotec Pharmalab Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Total gross capex invested as of June 30, 2026: ₹1,475 Cr; estimated total by end FY27: ₹1,666 Cr.
- API (Steroids & Hormones): ₹644 Cr invested; fully generating revenue; asset turns ~1.5X.
- Complex Injectables (Dual Chamber Vials - DCV): ₹356 Cr invested (₹376 Cr est.); majority capacity reserved with strategic partner.
- Biotech CDMO Services (400 KL + 14 KL): ₹471 Cr invested (₹584 Cr est.); backed by take-or-pay customer agreements.
- New API Capex: ₹4 Cr invested, estimated ₹63 Cr total; currently in discussions.
- New biologics facility (14 KL) at Ujjain under construction.
- Biotech plant expansion at SEZ Pithampur (280 KL) commissioned; biomanufacturing facility at Ujjain (400 KL) commissioned.
- 600 KL new CDMO capacities to be initiated, backed by customer agreement, revenue to commence in next 6–12 months.
2 more points from Symbiotec Pharmalab Ltd's call on capex
Create a free account to keep reading this call
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Symbiotec Pharmalab Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Symbiotec Pharmalab Ltd said on order book & pipeline — free account, 30 seconds.
Symbiotec Pharmalab Ltd — Quarterly revenue & net profit
Symbiotec Pharmalab Ltd Q1 FY27 results — key figures
| ₹ Cr | Q1 FY27 | Q4 FY26 | QoQ |
|---|---|---|---|
| Revenue | 218 | 245 | -11% |
| Operating profit (EBITDA) | 45 | 62 | -27.4% |
| Operating margin | 21% | 25% | -4 pp |
| Profit before tax | 18 | 35 | -48.6% |
| Net profit (PAT) | 14 | 28 | -50% |
| EPS (₹) | 2.24 | 4.39 | -49% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹280 Cr, net profit ₹52 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Symbiotec Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharma (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
- Natural Capsules (Q1 FY27)
Revenue from Operations for Q1FY27: ₹48.71 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q1 FY27 investor presentation — and how it ra
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Symbiotec Pharmalab Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Symbiotec Pharmalab Ltd Q1 FY27 results?
Q1 FY27 consolidated revenue from operations: ₹218.2 crores, up 7% YoY from ₹203.2 crores in Q1 FY26 (Page 9). Q1 FY27 EBITDA: Rs. 45.2 Cr, down from Rs. 58.0 Cr in Q1 FY26 (22% decline YoY).
What is Symbiotec Pharmalab Ltd share price analysis?
Symbiotec Pharmalab Ltd currently shows a neutral. The stock trades at a P/E of 61.0 with a market cap of ₹7,037 Cr. Investors should review the full earnings analysis for detailed insights.
Is Symbiotec Pharmalab Ltd planning capital expenditure?
Total gross capex invested as of June 30, 2026: ₹1,475 Cr; estimated total by end FY27: ₹1,666 Cr.
Keep Symbiotec Pharmalab Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
